View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
March 25, 2021

LoA Update: Ocuphire’s Nyxol in mydriasis jumps 9 points in FDA approval likelihood after positive Phase III data

As of 17 March, the FDA likelihood of approval (LoA) for Ocuphire Pharma’s Nyxol (phentolamine mesylate) in mydriasis rose by 9 points, according to GlobalData’s LoA update.

By Sean Rai-Roche

As of 17 March, the FDA likelihood of approval (LoA) for Ocuphire Pharma’s Nyxol (phentolamine mesylate) in mydriasis rose by 9 points, according to GlobalData’s LoA update. The update comes after an announcement that Ocuphire’s Phase III MIRA-2 trial met its primary and multiple secondary endpoints.

Free Report
img

What was the hiring sentiment across Healthcare in 2021?

by GlobalData
Enter your details here to receive your free Report.

While Nyxol previously had a 48% LoA, this increased to 57% after the results using GlobalData’s analysis using a combination of machine learning and its proprietary algorithm. According to a 15 March company media release, Nyxol met its primary endpoint, with 49% of subjects treated with Nyxol returning to ≤ 0.2 mm of their baseline pupil diameter at 90 minutes, compared with just 7% on the placebo control arm (p <0.0001). It also hit multiple secondary endpoints, such as a statistically significant and more rapid return to normal pupil size across a range of dilating agents and iris colours, as well as a faster return to baseline pupil diameter at 60 minutes.

MIRA-2 evaluated Nyxol’s activity in speeding up the reversal of pharmacologically induced mydriasis in 185 patients. Participants were randomised 1:1 to receive Nyxol or a placebo one hour after receiving one of three mydriatic agents (phenylephrine, tropicamide, and Paremyd). Nyxol is a once-daily alpha-1 and alpha-2 adrenergic antagonist eye drop being developed for several indications in addition to mydriasis.

Sean Rai-Roche is a Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

Free Report
img

What was the hiring sentiment across Healthcare in 2021?

by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena